Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: A cross-sectional study in rural Burundi

British Journal of Clinical Pharmacology

Volumn 79, Issue 5, 2015, Pages 801-808

  Calcagno, Andrea ^a   Motta, Ilaria ^a   Milia, Maria Grazia ^b   Rostagno, Roberto ^a   Simiele, Marco ^a   Libanore, Valentina ^a   Fontana, Silvia ^a   D'Avolio, Antonio ^a   Ghisetti, Valeria ^b   Di Perri, Giovanni ^a   Bonora, Stefano ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

efavirenz; limited resource countries; nevirapine; pharmacokinetics; resistance

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BURUNDI; CD4 LYMPHOCYTE COUNT; CHILD; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; VENOUS BLOOD; VIRUS LOAD; VIRUS REPLICATION; BLOOD; BLOOD STAIN; DRUG EFFECTS; GENETICS; HIV INFECTIONS; ISOLATION AND PURIFICATION; PROCEDURES; RURAL POPULATION; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTI-HIV AGENTS; BLOOD STAINS; BURUNDI; CHILD; CROSS-SECTIONAL STUDIES; DRUG MONITORING; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEVIRAPINE; RURAL POPULATION; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84928340743     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12544     Document Type: Article

References (23)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013 (UNAIDS/JC2502/1/E'- Revised and reissued, November 2013). Available at http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/ (last accessed 7 December 2013).
2. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, Puvimanasinghe J, Avalos A, Mine M, Seipone K, Essex M, Degruttola V, Marlink RG,. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008; 22: 2303-2311.
3. Palombi L, Marazzi MC, Voetberg A, Magit NA,. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 2007; 21 (Suppl. 4): S65-S71.
4. Republique du Burundi, Conseil National de lutte contre le VIH/SIDA. Ministere de la Sante Publique et de la lutte contre le SIDA unite sectorielle du lutte contre le SIDA 'Schemas de prise en charge de l'infection par le VIH au Burundi'. Octobre 2010.
5. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM,. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. AIDS 2010; 10: 155-166.
6. Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, Munderi P, Katundu P, Kityo C, Robertson V, Yirrell DL, Walker AS, Gibb DM, Gilks CF, Kaleebu P, Pillay D, Development of Antiretroviral Treatment in Africa Virology Group, Trial Team. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. J Infect Dis 2010; 201: 106-113.
7. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, Vella S, Hall D, Beijnen JH, Hoetelmans RM,. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15: 1089-1095.
8. Gathe J, Andrade-Villanueva J, Santiago S, Horban A, Nelson M, Cahn P, Bogner J, Spencer D, Podzamczer D, Yong CL, Nguyen T, Zhang W, Drulak M, Quinson AM,. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice daily in treatment-naive HIV-1 infected patients. Antivir Ther 2011; 16: 759-769.
9. Drlica K, Zhao X,. Mutant selection window hypothesis updated. Clin Infect Dis 2007; 44: 681-688.
10. Keiser O, MacPhail P, Boulle A, Wood R, Schechter M, Dabis F, Sprinz E, Egger M, ART-LINC Collaboration of the International Databases to Evaluate AIDS (IeDEA). Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health 2009; 14: 1220-1225.
11. Van Oosterhout JJ, Brown L, Weigel R, Kumwenda JJ, Mzinganjira D, Saukila N, Mhango B, Hartung T, Phiri S, Hosseinipour MC,. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health 2009; 14: 856-861.
12. Rawizza H, Chaplin B, Meloni ST, Eisen G, Rao T, Sankalé JL, Dieng-Sarr A, Agbaji O, Onwujekwe DI, Gashau W, Nkado R, Ekong E, Okonkwo P, Murphy RL, Kanki PJ, APIN PEPFAR Team. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis 2011; 53: 1283-1290.
13. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, Fiscus SA, Nelson JA, Eron JJ, Kumwenda J,. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23: 1127-1134.
14. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach, Edition June 2013. Available at http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html (last accessed 7 December 2013).
15. Calcagno A, D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Baietto L, Siccardi M, Bonora S, Di Perri G,. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Br J Clin Pharmacol 2012; 74: 134-140.
16. D'Avolio A, Simiele M, Siccardi M, Baietto L, Sciandra M, Bonora S, Di Perri G,. HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. J Pharm Biomed Anal 2010; 52: 774-780.
17. De Requena DG, Bonora S, Garazzino S, Sciandra M, D'Avolio A, Raiteri R, Marrone R, Boffito M, De Rosa FG, Sinicco A, Di Perri G,. Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting. Antimicrob Agents Chemother 2005; 49: 3966-3969.
18. Gallant JE, Mehta SH, Sugarman J,. Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? Clin Infect Dis 2013; 57: 884-887.
19. Gunda DW, Kasang C, Kidenya BR, Kabangila R, Mshana SE, Kidola J, Kalluvya SE, Kongola GW, Klinker H,. Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-Western Tanzania. PLoS ONE 2013; 8: e75118.
20. Sungkanuparph S, Win MM, Kiertiburanakul S, Phonrat B, Maek-a-nantawat W,. HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting. Int J STD AIDS 2012; 23: 316-318.
21. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, Walumbe E, Emonyi W, Chan P, Carter EJ, Hogan J, Buziba N,. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49: 454-462.
22. Diouara AAM, Diop-Ndiaye H, Kebe-Fall K, Tchiakpè E, Ndiaye O, Ayouba A, Peeters M, Mboup S, Kane CT,. Dried blood spots for HIV-1 drug resistance genotyping in decentralized settings in Senegal. J Med Virol 2014; 86: 45-51.
23. World Health Organization. WHO manual for HIV drug resistance testing using dried blood spot specimens. July 2012. Available at http://apps.who.int/iris/bitstream/10665/75829/10661/WHO-HIV-12012.10630-eng.Pdf (last accessed 7 December 2013).